Introduction
Acute coronary syndrome (ACS) is one of the leading culprits of death worldwide. ACS refers to a spectrum of conditions compatible with acute myocardial ischemia and/or infarction that may arise from a sudden reduction in the coronary blood flow. Symptoms which occur because of a partial or total blockage of a coronary artery and cause myocardial ischemia (cells starving of oxygen) OR infarction (cell death) (1) . According to Turkish Statistical Institute, ACS is responsible for almost 40 % of death due to heart diseases in Turkey (2) . WHO report that the diagnostic criteria of ACS are a typical chest pain evocative of myocardial ischemia, changes in ST-segment or new Q waves development and altered cardiac enzymes (3) . The majority of emergent hospitalizations for ACS include ST segment-elevation myocardial infarction (STEMI) and Non-ST segment-elevation myocardial infarction (NSTEMI) (4) . Currently cardiac troponins and creatine kinase MB (CK-MB) fraction are the most common biomarkers used for the diagnosis of this disease in clinical practice. In STEMI there is an elevation of CK-MB fraction, troponin I or T above the cut off levels. NSTEMI is mostly because of necrosis of myocardium with the release of biochemical markers Troponins I or T and CK-MB (5, 6) . Although huge progress has been observed regarding diagnosis, treatment, and prognosis of ACS recently if the patient does not have symptoms, such as chest pain or atypical pain, STEMI or NSTEMI are may be unpredictable (7, 8) .
Recently, microRNAs (miRNAs), which are involved in the post-transcriptional regulation of genes, also come into focus to understand the molecular biology of ACS better. miRNAs are involved in the pathogenesis of the heart, and their expression levels change considering the pathologic conditions (9) . Among the miRNAs implicated in cardiac diseases, miR-1, miR-133a and miR-133b have also been detected in the plasma or serum of ACS patients. Thus, the miRNAs are of particular interest to clarify the difference between the mechanism of STEMI and NSTEMI. The present study aims to characterize and compare the circulating miR-1, miR-133a and miR133b expression levels in peripheral blood samples of ACS patients to determine their discriminative expression pattern of STEMI or NSTEMI. MiRNA was extracted from the peripheral blood samples through miRVana miRNA isolation kit (Thermo Fisher Scientific, Wilmington, Delaware, USA) according to the manufacturer's instructions. The amount and purity of miRNA for the samples were determined using the Nanodrop 2000 within one hour, 7 (12.9%) patients within 2 hours, 15 (27.8 %) patients within 3 to 6 hours, 7 (12.9 %) patients within 6 to 12 hours and 6 (11.2 %) patients within 12 to 24 hours admitted to the emergency department. Accordingly, patients were divided into five individual groups. Distribution of these patients is shown in Table 1 .
Material and Methods

Time-dependent Expression Status of Circulated miRNA in ACS:
In the whole population statistics, the expression of miR-1 was 6.91 fold, miR-133a was 2.73 fold, and miR-133b was 2.65 fold upregulated in ACS patients in compare to control group (P= 0.40509; P=2.31700 and P= 0.56716; respectively). However, the expression levels of these miRNAs fluctuated time dependently. From 1st hour to 12th hour the expression level of miR-1 was up-regulated in all patients (p< 0.05 or fold change > 2) in comparison to control group. However, between 12th and 24th hours, the expression level was in normal levels. miR-133a and miR-133b were up-regulated in Fig. 2 . Time dependent fold regulations of miR-1, miR-133a and miR-133b first 2 hours and within 6th to 12th hours. In 3th to 5th hours and after 12th hours their expressions were in normal levels ( Table 2) . When the expression levels of these miRNAs were evaluated comparatively between STEMI and NSTEMI patients, the time-dependent fluctuation of miRNA regulations disappeared, and unique, distinctive expression patterns were observed in STEMI and NSTEMI patients (Figure 1) . In comparison to control group, the expression of miR-1 was 5.87 fold and 2.65 down-regulated in STEMI subjects within the first two hours of chest pain. (P= 0.19630 and P=0.07963; respectively). However, the expression of miR-1 began to increase after the second hour; between 2th and 6th hours its expression observed 2.98 fold more than the control group (P=0.00172) and following hours from 6th to 12th hour the expression of this miRNA was 108.32 fold upregulated (P=0.00001). MiR-133a and miR133b demonstrated a similar expression curve with miR-1. Similarly, their expressions were downregulated in the first couple of hours and between 2th and 6th hours although they were still in normal expression levels, they turned to increase. After 6th hours, miR-133a was 22.69 fold, miR-133b was 15.22 fold upregulated (P=0.00174 and P=0.04519; respectively, Table 3 ). The regulations of the miRNAs were in an opposite direction in NSTEMI cases to STEMI cases ( Figure  2 ). In case of NSTEMI, in compare to control group, the expression of miR-1 was significantly increasing within first two hours of chest pain (in 1st hour: 228.73 fold. P= 0.07931; in 2nd hour: 261.30 fold. P= 0.00002). However, after the second hour, the expression of miR-1 tended to decrease. Between 2nd and 6th hours its expression observed 69.46 fold (P=0.00033) and between 6th to 12th hour it was 5.32 fold upregulated (P=0.02244). Following hours from 12th to 24th hour the expression of this miRNA was in normal levels (1.78 fold; P=0.05571). In addition, the expression of miR-133a and miR-133b were significantly upregulated in six hours with a tendency to decrease. miR-133a in between 6th and 12th hours and miR-133b in between 12th to 24th hours decreased to normal expression levels (Table 4, Figure  2 ). Correlation Between Diagnostic Parameters and miRNA Expressions: The expressions of miR-1, miR-133a and miR-133b were in negative correlation with CK-MB in NSTEMI group and were in positive correlation in STEMI group (P> 0.05; Table 5 ). However, there was no correlative association between Troponin T levels and miRNA expression neither in STEMI nor NSTEMI patients (Table 6 ).
Discussion
In the treatment and prognosis of ACS, rapid and correct diagnosis is crucial. Cardiac troponins and CK-MB are the most commonly used biomarkers for ACS. However, their clinical value is limited (11) . Recent studies highlighted the role of altered miRNA expressions in the formation of cardiac diseases (11, 12) . Some of these miRNAs, such as miR-1, miR133a and miR-133b, which are expressed in heart tissue, are also associated with ACS (11, 12) . Although these miRNAs are expressed in heart tissue, secretoms of heart tissue cells, such as microvesicles, exosomes, microparticles and lipoprotein complexes, consist of these miRNAs and can be detected in serum or plasma. Circulating muscle-derived miRNAs may leak out of the necrotic myocardium and release into the circulation during the early stages of ACS (13−15) . MiRNA levels in serum or plasma remain stable in prolonged room temperature incubation or freezethawed multiple times (11, 16) . Therefore, miRNAs which are secreted by cardiac cells and accumulated in the blood may provide unique knowledge to contribute understanding of mechanism of ACS and may open a new frame for diagnostic and therapeutic interventions (17) . Wang et al. (18) showed that the levels of muscle-enriched miR-1 increased in plasma of rats and human with ACS and showed a positive correlation with serum CK-MB level. On the other hand, in another clinical study from Cheng et al. (19) demonstrated that although plasma miR-1 level was significantly higher in ACS patients compared with non-ACS subjects, the increased plasma miR-1 was not in correlation with serum CK-MB level. Our were compatible with the studies that showed that levels of the circulating miR-1was 6.91 fold increased in ACS patients and was significantly higher than those in healthy volunteers (P= 0.40509). However, the fold regulation of this miRNA fluctuated timedependently. It is notable that reports on the regulation of circulating miR-133 in ACS are controversial. Wang et al. found out that miR-133 in increased levels in plasma of rats and human with ACS and reported a positive correlation with serum Troponin I (24). However, Ai et al.'s research showed that there was no significant difference in plasma level of miR-133 between ACS patients and healthy subjects (20) . In the present study, the expression level of miR-133a and miR-133b were 2.73 fold and 2.65 fold upregulated in plasma of ACS patients. Although in this frame our data support Wang et al.'s findings, the fold regulations of these miRNAs were also fluctuated time dependently. As reported above, there are several studies that underline the altered expressions of miR-1, miR-133a and miR-133b in ACS. However, the knowledge about their distinct regulation pattern in STEMI and NSTEMI is still insufficient. The diagnostic factors of ACS may also demonstrate different patterns between STEMI and NSTEMI cases. Evaluation of these cases individually may clarify the current inconsistent data about their miRNA expression profile. Therefore, in the present study, we evaluated the different expression pattern of miR-1, miR-133a and miR-133b between STEMI and NSTEMI cases comparatively. Our findings showed that these miRNAs regulation is in the opposite direction between STEMI and NSTEMI. In STEMI patients, in the first 2 hours miR-1 was 5.87 and 2.65 folds down-regulated and became observable between 2th and 6th hours (2.98 fold) and between 6th and 12th hours, it was significantly (108.35 fold) induced (P< 0.05). Inversely; in NSTEMI patients, in the first 2 hours miR-1 was 228.73 fold and 261.30 fold higher than control subjects. However, between 2th and 6th hours, the expression of miR-1 reduced to 69.46 fold, between 6th to 12th hours it reduced to 5.32 fold (P<0.05) and after 12 hours it reduced to similar levels of control subjects. MiR-133a and miR-133b were also demonstrated similar expression patterns with miR-1 in STEMI and NSTEMI cases. In the first 6 hours of STEMI, there were no significant differences between the expression of these miRNAs and control subjects (fold regulation< 2 fold). However, from 6th to 12th hours their expressions were considerably increased (22.69 fold and 15.22 fold, respectively; P<0.05). On the other hand; these miRNAs were in high levels during the first six hours of ACS in NSTEMI patients. MiR-133a decreased to normal levels following times of the 6th hour, and miR-133b decreased to normal levels between 12th and 24th hour. Thus, our data demonstrated that, in STEMI, and NSTEMI patients the expression levels of these miRNAs might change in different directions depending on measuring time. This finding may clarify the reason for time-dependent fluctuation in the expression level of these miRNAs in the evaluation of whole patients in the same sample group. Troponin T is a part of troponin complex expressed in skeletal and cardiac myocytes. The cardiac subtype of troponin T is released into the blood stream when heart muscle damaged (21) . CK isozymes provide specific information about the localization of tissue injury. CK enzymes rise when muscle cells damaged in the body. CK-MB is presented, to various degrees, in heart muscle (25% to 46% of CK activity) and also to a minor degree in skeletal muscle (<5%) (22, 23) . In people with chest pain, total CK and CK-MB levels are measured to realize a potential heart attack. Because total CK height indicates damage to the heart or other muscles, CK-MB helps distinguish these two damaged areas. CK-MB is 2-3% of total serum CK. If CK-MB exceeds 6%, it is accepted as pathological values. In ACS, usually, total CK starts to increase in 3-4 hour following chest pain, reaches the maximum in 24 hours and decrease to normal values in three days (24) . Current knowledge about the diagnostic factors of ACS and miRNA is also insufficient. Cheng et al. (19) did not find out any link between plasma miR-1 expression and CK-MB. On the other hand, a positive correlation was reported between the elevated plasma miR-133 and Troponins. Plasma levels of miR-133a and miR-133b were reported as upregulated in STEMI patients about 156 minutes after the occurrence of ACS, consistent with the time course of change in Troponin T level (14, 25) . Approximately two-thirds of ACS occurs outside the hospital, and most of these patients apply to the hospital not immediately but within 24 hours after feeling the chest pain. Thus, the association of altered expressions of miR-1, miR-133a and miR-133b and diagnostic factors of ACS may be time depended. Therefore, in the present study, we evaluated the different expression pattern of miR-1, miR-133a and miR-133b and the association of these miRNAs with diagnostic factors of ACS, such as Troponin T and CK-MB in STEMI and NSTEMI cases in a time depended manner. Unlikely to previous studies, in STEMI patients, miR-1, miR-133a and miR-133b were in positive correlation with CK-MB during the first 12 hours. Due to any STEMI patients did not apply to emergency department between 12th and 24th hours of chest pain, we could not evaluate the correlation of these miRNAs with other diagnostic factors of ACS for this time period. On the other hand, in case of NSTEMI, as expected, the expressions of miRNAs were in negative correlation with CK-MB during the first 24 hours. However, we could not determine a continue correlation with a stability between miRNAs and Troponin T. In conclusion, supporting previous literature, we identified that, circulating miR-1, miR-133a and miR133b expressions were significantly increased in ACS cases. We demonstrated the considerably higher expression levels of these miRNAs in NSTEMI cases in compare to STEMI cases during the first 6 hours of chest pain. We also defined that although these miRNA expressions increase during ACS in both STEMI and NSTEMI patients, their expression pattern differs between these two groups of patients depend on the time of evaluation. While miRNA expressions were in positive correlation with CK-MB in STEMI, they were in negative correlation in NSTEMI patients for the first 24 hours. Hence, we suggest that time dependent miR-133a and miR-133b expression pattern of ACS patients are likely to guess the progression of coronary heart disease. Advanced functional and in-vivo studies to evaluate the association between the miRNA carrier vesicle releasing time of heart tissue and their expression levels in peripheral blood and larger cohort validations are required.
